IHC: A "Stain," or an "In Situ" Tissue-based Immunoassay?
In its traditional use as a "stain" the IHC result is judged by a tinctorial reaction, the generation of color, positive or negative, for the cell or tissue of interest. This judgment is purely qualitative and it is subjective, depending upon the eye and experience of the pathologist, albeit with reference to control tissues, the assessment of which also is subjective.
In the long use of IHC as a "special stain" we have acquired some very bad habits. Laboratory technicians and pathologists are accustomed to adjusting the IHC protocol, changing concentrations or incubation times, or retrieval methods, or reagents to achieve "good" stains on tissues prepared at a particular institution, where "good" is defined as a result that "pleases the eye" of the user pathologist. Although this approach may be acceptable for IHC stains, when interpreted in the light of experience and proper controls, it is a recipe for disaster when transferred to companion diagnostics, when absolute reproducibility and some form of quantification are required.
Companion Diagnostics should be Regarded as Assays, Not as Stains 7
When IHC is used as the basis for a companion diagnostic there is an implied transition from a stain to an assay, with elements of quantification. The question is no longer one of whether the target protein is present (a positive "stain"), but rather it is a question of how much of the target protein (or analyte) is present, requiring quantitative assessment (How much per cell? What percentage of cells?). 7, 8 The enzyme linked sorbent assay (ELISA) is a "gold standard" method for measurement of the amount of an analyte (eg, protein) in blood and other biological fluids. Measurements by ELISA are both accurate and reproducible, based upon "color generated" under strictly controlled conditions and measured against a calibration or reference standard. ELISA uses a specific antibody and a chromogenic detection system analogous in principle to IHC, 7 but, whereas ELISA gives results that are widely accepted to be both quantifiable and reproducible, IHC does not. The reasons are related to differences in practical performance and are potentially open to improvement for IHC (Table 1 ).
COMPANION DIAGNOSTICS: IN THE BEGINNING
Approved by the FDA in 1998, the "Her2 test" (HercepTest, Agilent; Dako, Carpinteria, CA) served as the prototypic companion diagnostic for IHC. A positive result classifies a patient as a "responder" to targeted therapy with Trastuzumab (Herceptin; Genentech, CA) directed against ERBB2 (HER2) "over"expressed on the cancer cell membrane. Approval of the test by the FDA was (and is) specific for all aspects of the test, including reagents, cell line controls, protocol, and scoring parameters, as defined in the approved package insert. 9 The originally approved scoring method was "semiquantitative," performed by a pathologist with a microscope: 0, 1+, 2+, and 3+, based upon the intensity of membrane staining, percentage of stained cells, and pattern of staining (partial or complete). Scores of 0 and 1+ were deemed negative (nonresponders) and 2+ and 3+ were classed as positive (responders). Other vendors have developed approved HER2 tests that are similar, but not identical. More recently, computer-driven algorithms performed on digital Whole Slide Images have been approved by the FDA as providing interpretation of HER2 results that in clinical trials is equivalent to that obtained by experienced pathologists with the manual method.
In addition, fluorescent in situ hybridization testing for HER2 gene amplification has emerged as a second "approved" test, and often is used as a supplementary method when IHC HER2 testing gives results that are "equivocal." In practice, these often are cases in which the IHC results are close to the scoring threshold for positive versus negative. This ability to reflex "equivocal" cases to a second independent method will not be available for many upcoming companion diagnostics, placing much greater reliance upon a scoring method that is easily taught and easily learned, and is effective and reproducible, especially at the threshold. Computer-based readout with reference to calibration standard
Mostly manual and subjective *Fixed cell line sections included in approved diagnostic kits are prepared so as to give consistent protein expression, but cannot be used to calibrate (measure) results in FFPE tissues as preparation and fixation methods differ.
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Growing Demands for Companion Diagnostics and IHC
Over the past decade the number of potential targeted therapies has grown exponentially, [10] [11] [12] [13] [14] and with it the need for companion diagnostics. Approval of a "companion diagnostic" depends upon clinical demonstration of the effectiveness of the test in classifying responders versus nonresponders, necessitating close collaboration between the manufacturers of the drug and the test. Any change in parameters of the approved test (reagents, protocol, scoring) requires revalidation, and a new approval process. Indeed, within months of approval of the original HercepTest in 1998, publications showed that changing the test conditions changed the test results, affecting clinical sensitivity with respect to responders and nonresponders. The issue of reproducibility of IHC testing for Her2 remains a concern to the present day and scoring guidelines have changed more than once. [15] [16] [17] [18] Many targeted therapies have, as their targets, proteins. IHC, demonstrating both the protein and its cellular localization, is, therefore, in theory the ideal method upon which to base a companion diagnostic. Here there are lessons to be learned from more than a decade of IHC testing for Her2 (18) . Under ideal circumstances, differences in levels of Her2 expression as detected by the test (0, 1+, 2+, 3+) are directly reflective of the biology of the tumor (1) in Table 2 ), but experience has shown that many other factors influence the reported result, affecting reproducibility of test results and their interpretation ( Table 2 ).
Variations in Sample Acquisition, Preparation, and Fixation
The issue of inconsistent sample preparation has emerged as a key factor affecting the reproducibility of an IHC test, extending from "warm ischemia," through "cold ischemia" (specimen transport), to fixation and processing of FFPE tissue, which is generally the material available for testing in the clinical arena. The adverse impacts of cold ischemia and fixation time vary independently of one another, and are different for different antigen/antibody pairings, ranging from minimal for some to catastrophic for others. In addition, there is an almost complete lack of hard data describing the behavior of specified proteins or analytes under these different conditions.
One approach to inconsistent sample preparation has been the development of guidelines, including minimizing ischemia time, and defining (and documenting) fixation time. [17] [18] [19] [20] There is an expectation that outcomes will be improved by this approach, but logistical and cost issues are formidable, and there is presently no reliable method of monitoring compliance with guidelines for any particular tissue specimen, either within an institution or across institutions.
Another approach has been to develop "molecular friendly fixatives," purported to have fewer adverse effects on the "antigenicity" of proteins than experienced with FFPE tissues. Again, the challenges of orchestrating change by multiple laboratories to an improved fixative, even if all could agree upon what that fixative might be, have, to date, proved insurmountable. The problem is compounded by the inevitable outcome of gradually accumulating "new fixed" tissues that are not comparable to archival FFPE tissues for IHC (or molecular analysis), and by attendant differences in basic morphology, whether real or perceived.
A third approach is based upon "qualifying" an FFPE tissue section as suitable for performance of a particular IHC test (assay) by use of internal control proteins. This proposal parallels "routine practice" in molecular testing, whereby measurement of a "housekeeping gene" or product (eg, actin) serves as a quality control 21, 22 and under specified conditions may serve as a calibration or reference standard. 7, 8 
Multiplicity of Reagents and Methods
Studies by external QC organizations, such as NordiQC 23 and UKNEQAS, 24 have shown an astonishing range of variation among different laboratories with respect to choice of reagents, retrieval methods, and staining protocols (automated or manual). For example, in 1 UKNEQAS survey encompassing 365 laboratories performing an "IHC stain" for keratin, 26 different primary antibodies were used, with >20 different detection systems from 13 vendors, using 17 different autostainers or manual methods. This enormous diversity represents a great problem for the reproducibility of IHC in general, and becomes a critical issue for "companion diagnostics," where the question asked of the test is much more rigorous; not just whether the protein is present (a positive stain) but how much protein is present on a comparative basis from case to case? Just as the question is more rigorous so the demands of test performance are much more rigorous.
Some of these problems stemming from diversity of reagents and protocols are addressed by use of "kits" (IVDs) approved by the FDA or by comparable agencies in other countries, and by automation, which has the side benefit of "forcing" some standardization by restriction in practical choice of reagents and protocol. The use of an FDA-approved test (class III, IVD) restricts the performing laboratory to a specified reagent set and a closed protocol, and to an internal validation process that provides some assurance of run to run stability. It must be remembered that any deviation from reagents or protocol negates validation. Such deviations include differences in antigen (or epitope) retrieval protocols (solutions and heating methods), which have been shown to have profound effects upon the ability to demonstrate proteins by otherwise standard protocols (in the UKNQAS survey cited above 17 different retrieval solutions were utilized). 24 
Choice of Control Cells or Tissues, and Lack of Uniform Reference Standard(s)
Recent reviews in AIMM [25] [26] [27] reflect increased focus on the critical importance of using proper controls to achieve high-quality consistent IHC results. To a large extent this focus on improved controls has been driven by the desire to use IHC for companion diagnostics.
The basic controls used in IHC "staining" are listed in Table 3 . Other controls exist, and more extensive treatment of the topic of controls for IHC may be found in specialized texts and manuals. 20, [26] [27] [28] [29] The following brief discussion emphasizes the need for higher order controls if IHC is to be used successfully in companion diagnostics.
Most approved IVD companion diagnostics require performance of negative reagent controls (NRCs) as part of the approved protocol. This mandate reflects concern that a false-positive result would lead to inappropriate administration of the "companion" drug to a patient who would be unlikely to benefit, with associated possible side effects, not to mention high economic cost. In view of the recent relaxation of CAP recommendations, allowing performance of NRC "at the discretion of the laboratory director" when using polymer-based detection methods, 25, 26 it is possible that this requirement might at some point be relaxed; however, at present, if required by the approved protocol, NRCs should be performed.
External positive controls are important to demonstrate that the companion diagnostic IHC assay produces the expected signal in tissue (or cells) known to contain the target analyte. FDA-approved "kits" such as the HercepTest include sections of FFPE cell line pellets (negative, low, and high positive) for this purpose, meeting general recognition that a positive control should be of a relatively low signal intensity so as to detect decreased assay performance. 27 Note that sections of known positive cases, even when obtained in-house from other patients, give only general information as to the suitability of sample preparation, including FFPE fixation. [26] [27] [28] [29] Only true tissue internal controls meet the requirements of having undergone all stages of sample preparation and IHC protocol in a manner identical to the test analyte, because, by definition, the internal control protein is located in the same tissue section alongside the test protein.
Inconsistencies in Scoring of Result (Intensity Vs. Percentage of Positive Cells)
Internal tissue controls are used by pathologists, almost unthinking, in almost every case, exemplified by evaluating plasma cells when staining for k or l light chain, or residual normal breast ducts in a case of breast cancer *External because the tissue is "external" to the patient test section, as opposed to "internal." Such tissue is usually obtained "in-house," which means that sample preparation and fixation may be similar to the test tissue but is not identical. Tissues obtained from sources outside of the laboratory are external in another sense, and may have undergone even more diverse preparation; purchased multitissue arrays and cell line pellets are in this category.
wIt is not possible today to provide identical FFPE tissues as part of approved IVD companion diagnostic kits; FFPE cell line pellets are often used instead (Table 1) . These cell line pellets do not control for sample preparation and FFPE.
CAP indicates College of American Pathologists; CIQC, Canadian Immunohistochemistry Quality Control; FFPE, formalin-fixed paraffin-embedded.
that is otherwise nonreactive for ER ( Fig. 1A) . Indeed in the 1980s Hector Battifora and others adopted the notion of utilizing observed positive staining for vimentin ( Fig. 1B) as a kind of surrogate marker that fixation had left at least 1 protein sufficiently intact for successful IHC staining. Assessment was purely qualitative. The use of internal or intrinsic proteins has been proposed as a method for qualifying a specimen as suitable for IHC staining. 7, 8, 22 This approach may also be extended to form a more extensive system of "quantifiable internal reference standards" (QIRS), as a means of rendering a quantitative measurement by IHC. 7, 8 The method would require the minimum of a "double IHC stain," demonstrating both the internal reference standard (protein) and the test analyte (protein) in the same tissue section, followed by image analysis for comparative measurement and quantification. Digital image analysis is necessary, because the subtle changes in intensity and distribution for precise measurement cannot be assessed by the human eye.
Digital image analysis also will be essential when "multiplex" IHC protocols are used for improved discrimination among cells types, as when attempting to score localization of a biomarker on tumor cells versus other cell types (eg, carcinoma cells vs. macrophages for PD-L1) (Figs. 1C-F). Such approaches already have been used in fluorescence-based systems for improved quantification and for cell recognition, 30, 31 and are equally applicable in high-order multiplex staining of bright field images that are obtained by repeated sequential staining of biomarkers on the same tissue section. 32, 33 In Situ Proteomics Today, classification of cancers (patients) into responders and nonresponders for a plethora of targeted therapies cannot be achieved by pathologists and microscopy alone, 10 nor is the answer entirely to be found in newer molecular methods, when practiced upon extracts of "biopsy tissues," in which the proportion, or even the presence, of cancer cells is unknown, and all aspects of heterogeneity of expression by tumor and stromal elements are lost.
The prototypic companion diagnostic for HER2 has survived to this day, despite ongoing concerns with regard to accuracy and reproducibility. As discussed, some of these concerns were attributable to poor sample preparation or to variations in protocol, but others related to lack of reproducibility of scoring by pathologists, relating to both intraobserver and interobserver consistency. The introduction and approval of digital algorithms applied to Whole Slide Image was a response to this last problem, with improvement in consistency, 18 even though the potential capability of the image analysis method was restricted by an approval process that sought only to replicate the semiquantitative scoring achieved by pathologists with a microscope. In this respect, the full potential of computer-assisted image analysis for quantification and measurement in the context of a morphologic environment has yet to be exploited.
The demand for precision, objectivity, and reproducible measurement does not necessarily represent the end of the microscope or of "Surgical Pathology," but it does represent the end of a long beginning, how for a century and a half the histolopathologic classification of a tumor has been a primary factor in the selection of therapy. 30 Optimistically, these new demands may repre-sent the beginning of a new era, supplementing morphologic judgment with precise measurement of proteins in tissue and individual cells, tissue-based immunoassays, "in situ proteomics" as it were.
SUMMARY
With the pending flood of new companion diagnostics, some of which are IHC based, the problems encountered with the HER2 test will be revisited, time and time again. The outcome is not difficult to predict by reference to the history of the introduction of ELISA into the clinical laboratory (Table 1 ). Already considerable attention is being given to all aspects of tissue sample preparation for IHC, with attempts to document and standardize across institutions. However, the logistical and cost issues are formidable and it is not likely that the level of standardization achieved on blood or fluid samples for ELISA can ever be achieved for tissues and IHC. It appears probable, therefore, that some method of "qualifying" a tissue sample as suitable for performance of a particular IHC companion assay by use of an internal control will become necessary. Furthermore, by analogy with ELISA in the clinical laboratory, automation of IHC for companion diagnostics is inevitable, with reagents and protocols subject to increasingly rigorous approval processes, using closed assay systems, that cannot be "tweaked" to get more intense staining to compensate for a deficient FFPE process. In the face of poorly controlled sample preparation, the mantra-"don't tweak the protocol; fix the fixation"-comes to mind.
